CO5070670A1 - Taloproteinasas de arilsulfonamidas y estatinas - Google Patents

Taloproteinasas de arilsulfonamidas y estatinas

Info

Publication number
CO5070670A1
CO5070670A1 CO99016109A CO99016109A CO5070670A1 CO 5070670 A1 CO5070670 A1 CO 5070670A1 CO 99016109 A CO99016109 A CO 99016109A CO 99016109 A CO99016109 A CO 99016109A CO 5070670 A1 CO5070670 A1 CO 5070670A1
Authority
CO
Colombia
Prior art keywords
statin
taloproteinases
arilsulphonamid
pharmaceutically acceptable
salt
Prior art date
Application number
CO99016109A
Other languages
English (en)
Spanish (es)
Inventor
Roger Schofield Newton
Bruce David Roth
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO5070670A1 publication Critical patent/CO5070670A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO99016109A 1998-03-17 1999-03-16 Taloproteinasas de arilsulfonamidas y estatinas CO5070670A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
CO5070670A1 true CO5070670A1 (es) 2001-08-28

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99016109A CO5070670A1 (es) 1998-03-17 1999-03-16 Taloproteinasas de arilsulfonamidas y estatinas

Country Status (18)

Country Link
EP (1) EP1063991A1 (enExample)
JP (1) JP2002506818A (enExample)
KR (1) KR20010041916A (enExample)
AR (1) AR018113A1 (enExample)
AU (1) AU1591699A (enExample)
BR (1) BR9815745A (enExample)
CA (1) CA2309588A1 (enExample)
CO (1) CO5070670A1 (enExample)
GT (1) GT199900039A (enExample)
HN (1) HN1999000029A (enExample)
MY (1) MY140504A (enExample)
NZ (1) NZ505994A (enExample)
PA (1) PA8469001A1 (enExample)
PE (1) PE20000348A1 (enExample)
SV (1) SV1999000026A (enExample)
UY (1) UY25436A1 (enExample)
WO (1) WO1999047138A1 (enExample)
ZA (1) ZA992106B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
CA2590278A1 (en) 2004-12-15 2006-06-22 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
EP1948599A1 (en) * 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US20110182851A1 (en) * 2008-07-11 2011-07-28 Jan Nilsson Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284142B6 (sk) * 1995-11-02 2004-10-05 Warner-Lambert Company Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku
SK282863B6 (sk) * 1996-05-17 2002-12-03 Warner-Lambert Company Bifenylsulfonamidy, ich použitie a farmaceutické prostriedky na ich báze
MXPA99001974A (es) * 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
JP2002506818A (ja) 2002-03-05
CA2309588A1 (en) 1999-09-23
KR20010041916A (ko) 2001-05-25
MY140504A (en) 2009-12-31
EP1063991A1 (en) 2001-01-03
BR9815745A (pt) 2000-11-14
GT199900039A (es) 2000-09-06
UY25436A1 (es) 2001-10-25
AU1591699A (en) 1999-10-11
PE20000348A1 (es) 2000-05-22
WO1999047138A1 (en) 1999-09-23
AR018113A1 (es) 2001-10-31
NZ505994A (en) 2003-10-31
HN1999000029A (es) 1999-09-29
ZA992106B (en) 1999-09-30
PA8469001A1 (es) 2002-09-17
SV1999000026A (es) 2000-01-18

Similar Documents

Publication Publication Date Title
IS5739A (is) Efnasambönd óstöðugra DP IV-lata
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
DE69434977D1 (de) HIV Protease Inhibitoren
IL110752A0 (en) Pharmaceutical composition for an hiv protease inhibitor
GR3030719T3 (en) Sulfonamide inhibitors of hiv-aspartyl protease.
EA199900373A2 (ru) Фармацевтические композиции
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
NO990548L (no) Inhibitorer for cystein-protease
HUP0103283A3 (en) Pyrazinone protease inhibitors, pharmaceutical compositions containing them and use of the compounds
FI935778A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
BG103425A (en) Pharmaceutical composition
DE69907977D1 (de) Pyrrolobenzodiazepine
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
FI954580L (fi) HIV-proteaasin estäjiä farmaseuttisissa yhdistelmissä käytettäväksi AIDSin hoitoon
NO20005196L (no) Substituerte pyrrolidinhydroksamat-metallproteaseinhibitorer
PT1047450E (pt) Combinacoes inibidor ace - inibidor mmp
PT831826E (pt) Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
FI962488L (fi) HIV:n proteaasin inhibiittoreita
FI935780A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
SE9601556D0 (sv) New pharmaceutical formulation of a thrombin inhibitor for parenteral use
CO4970816A1 (es) Combinaciones de estatina-eter carboxialquilico
FI935779A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
NO932130D0 (no) Hemmere av hiv-protease som er nyttige for behandling av aids
GB9907571D0 (en) Compounds
CO5070670A1 (es) Taloproteinasas de arilsulfonamidas y estatinas